For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
News Release
FDA deserves credit for approval pancreatic cancer drug
The FDA on August 26 approved a new breakthrough drug to treat pancreatic cancer. CEI Senior Fellow and Economist Jeremy Nighohossian praised…
Blog
What Trump’s vaccine executive order actually does
Yesterday, President Trump signed an executive order directing federal health agencies to revise childhood vaccine recommendations, reducing the number of vaccines recommended for…
Blog
Trump administration decision highlights disastrous Part D redesign
The Trump administration recently announced the end of a demonstration project that was pulled together by the Biden administration as the Inflation Reduction…
Search Posts
Washington Post
US Backs Pediatric Tests In Reversal on Drug Safety
Op-Eds
FDA Overreaches
Who could possibly oppose a pediatric-testing rule for drugs? For starters, physicians and parents who realize that while this rule is supposed to protect children,…
Washington Post
The Need to Test Drugs on Children
News Release
New York Times Attacks CEI On FDA’s Pediatric Rule
Copyright © 2002 The New York Times <?xml:namespace prefix = o ns = “urn:schemas-microsoft-com:office:office” /> The Bush administration senselessly…
News Release
Food Expert Applauds Science Journal’s Recognition Of Flawed Mexican Corn Study
Washington, D.C., April 4, 2002-The Competitive Enterprise Institute is encouraged by an admission today from the science journal Nature that a controversial article on…
Washington Post